Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001571049-16-011761
Filing Date
2016-02-12
Accepted
2016-02-12 21:01:49
Documents
1
Period of Report
2016-02-10

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT t1600413_x2-bfi.html 4  
1 OWNERSHIP DOCUMENT t1600413_x2-bfi.xml 4 7312
  Complete submission text file 0001571049-16-011761.txt   9062
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Issuer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666
Business Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666 2013297300
BFI Co., LLC (Reporting) CIK: 0001601607 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-36410 | Film No.: 161422301